



AATMAJ HEALTHCARE LIMITED



Corporate Identification Number: U85100GJ2014PTC079062

Our Company is engaged in Healthcare services. Our Company was originally incorporated on March 10, 2014 as "Aatmaj Healthcare Private Limited" bearing corporate identification number U85100GJ2014PTC079062 as a private limited company, under the provisions of the Companies Act, 1956 vide certificate of incorporation dated March 10, 2014 issued by the Registrar of Companies, Gujarat, Dadra and Nagar Haveli. Our Company was formed by promoters namely Dr. Tushar Suvagiya and Dr. Subhash Padmani with the main object as, and presently engaged in the business, to run nursing homes and healthcare centers, for the reception and treatment of persons suffering from illness or of persons requiring medicinal attention or rehabilitation and to provide medical relief in all branches of medical sciences etc. Dr. Ravi Apte joined our Company as Director in the month of April 2015. Our Company was converted into a Public Limited Company pursuant to the special resolution passed by the shareholders at the extraordinary general meeting of our Company held on November 16, 2022 and consequent upon conversion the name of our Company was changed to "Aatmaj Healthcare Limited" vide a fresh certificate of incorporation dated December 6, 2022 bearing corporate identification number U85100GJ2014PLC079062 issued by the Registrar of Companies, Ahmedabad.

Registered office: "Jupiter Hospital", Opp. ICAI Bhavan, Sunpharma Ataladra Road, Vadodara - 390012, Gujarat, India.
 Contact Person: Mrs. Radhika Hissaria, Company Secretary & Compliance Officer
 Mob No: +91 9714059465 | Email Id: cs@jupiterhospitalvadodara.com | Website: www.jupiterhospitalvadodara.com

PROMOTERS OF THE COMPANY: DR. TUSHAR SUVAGIYA, DR. SUBHASH PADMANI AND DR. RAVI APTE

THE ISSUE

INITIAL PUBLIC ISSUE OF 64,00,000 EQUITY SHARES OF FACE VALUE OF ₹ 5/- EACH ("EQUITY SHARES") OF AATMAJ HEALTHCARE LIMITED ("OUR COMPANY" OR "THE ISSUER COMPANY") FOR CASH AT A PRICE ₹60/- PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹55/-PER EQUITY SHARE) ("ISSUE PRICE") AGGREGATING TO ₹ 3,840.00 LAKHS ("THE ISSUE"), OF WHICH 3,21,000 EQUITY SHARES OF FACE VALUE OF ₹5/- EACH FOR A CASH PRICE OF ₹60/- PER EQUITY SHARE, AGGREGATING TO ₹ 192.60 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER ("MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 60,79,000 EQUITY SHARES OF FACE VALUE OF ₹ 5/- EACH AT AN ISSUE PRICE OF ₹60/- PER EQUITY SHARE AGGREGATING TO ₹3,647.40 LAKHS (IS HERINAFTER REFERRED TO AS THE "NET ISSUE"). THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 28.32% AND 26.90%, RESPECTIVELY OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY. FOR FURTHER DETAILS, PLEASE REFER TO SECTION TITLED "TERMS OF THE ISSUE" BEGINNING ON PAGE NO. 309 OF THIS PROSPECTUS.

**THE FACE VALUE OF THE EQUITY SHARES IS ₹ 5.00/- EACH AND
 THE ISSUE PRICE IS ₹ 60.00/- PER EQUITY SHARE
 THE ISSUE PRICE IS 12 TIMES OF THE FACE VALUE OF THE EQUITY SHARES**

In terms of Rule 19(2)(b)(i) of the SCRR this Issue is being made for at least 25% of the post-issue paid-up Equity Share capital of our Company. This issue is being made through Fixed Price process in accordance and compliance with Chapter IX and other applicable provisions of SEBI ICDR Regulations wherein a minimum 50% of the Net Issue is allocated for Retail Individual Investors and the balance shall be offered to individual applicants other than Retail Individual Investors and other investors including corporate bodies or institutions, QIBs and Non-Institutional Investors. However, if the aggregate demand from the Retail Individual Investors is less than 50%, then the balance Equity Shares in that portion will be added to the non-retail portion offered to the remaining investors including QIBs and NIIIs and vice-versa subject to valid applications being received from them at or above the Issue Price. Additionally, if the Retail Individual Investors category is entitled to more than 50% on proportionate basis, the Retail Individual Investors shall be allocated that higher percentage. All potential investors shall participate in the Issue only through an Application Supported by Blocked Amount ("ASBA") process including through UPI mode (as applicable) by providing details of the respective bank accounts and / or UPI IDs, in case of RIIIs, if applicable, which will be blocked by the Self Certified Syndicate Banks ("SCSBs") for the same. For details in this regard, specific attention is invited to "Issue Procedure" beginning on page no. 321 of this Prospectus. A copy will be filed with the Registrar of Companies as required under Section 26 and Section 28 of the Companies Act, 2013.

MINIMUM APPLICATION OF 2000 EQUITY SHARES AND IN MULTIPLES OF 2000 EQUITY SHARES THEREAFTER

**ISSUE PROGRAM OPENS ON: MONDAY, JUNE 19, 2023
 CLOSES ON: WEDNESDAY, JUNE 21, 2023**

ASBA* Simple, Safe, Smart way of Application- Make use of it!!! *Applications Supported by Blocked Amount ("ASBA") is a better way of applying to issues by simply blocking the fund in the bank account. For details, check section on ASBA below. Mandatory in Public Issues. No Cheque will be accepted.

UPI – Now Mandatory in ASBA for Retail Individual Investors (RIIs)
 Investors are required to ensure that the Bank Account used for bidding is linked to their PAN.
UPI – Now available in ASBA for RIIs applying through Registered Brokers, DPs and RTAs. RIIs also have option to submit the application directly to the ASBA Bank (SCSBs) or to use the facility of linked online trading, demat and bank account.
 For details on ASBA and UPI process, please refer to the details given in Application Form, Abridged Prospectus, General Information Document for investing in the public issue and also please refer to chapter "Issue Procedure" beginning on page no 321 of the Prospectus.
 ASBA Application Forms can be downloaded from the website of National Stock Exchange of India Limited ("NSE") and can be obtained from the list of banks that is displayed on the website of the Securities and Exchange Board of India ("SEBI") at www.sebi.gov.in.
 List of banks supporting UPI is also available on the website of SEBI at www.sebi.gov.in. For the list of UPI Apps and Banks live on IPO, please refer to the link www.sebi.gov.in.

PROPOSED LISTING: The Equity Shares Issued through the Prospectus are proposed to be listed on the EMERGE Platform of National Stock Exchange of India Limited ("NSE EMERGE") in terms of the Chapter IX of the SEBI (ICDR) Regulations, 2018, as amended from time to time. Our Company has received an In-Principle Approval Letter dated June 01, 2023 from National Stock Exchange of India Limited for using its name in the Prospectus for listing of our shares on the EMERGE Platform of National Stock Exchange of India Limited. For the purpose of this Issue, the Designated Stock Exchange will be the National Stock Exchange of India Limited ("NSE").

DISCLAIMER CLAUSE OF SECURITIES AND EXCHANGE BOARD OF INDIA ("SEBI"): Since the Issue is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, 2018, the Issue Document was not filed with SEBI. In terms of the SEBI ICDR Regulations, SEBI shall not issue any observations on the Issue Document. Hence, there is no such specific disclaimer clause of SEBI. However, investors may refer to the entire "SEBI Disclaimer Clause" on page no. 301 of the Prospectus.

DISCLAIMER CLAUSE OF NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE") (DESIGNATED STOCK EXCHANGE): It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the Offer Document has been cleared or approved by NSE nor does it certify the correctness or completeness of any of the contents of the Offer Document. The investors are advised to refer to the Offer Document for the full text of the "Disclaimer Clause of NSE" on page no. 302 of the Prospectus.

RISK IN RELATION TO THE FIRST ISSUE: This being the first public issue of our company, there has been no formal market for the securities of our company. The face value of the shares is ₹ 5.00/- per equity share and the Issue Price is 12 times of the face value.
The average cost of acquisition per Equity Share to our Promoters as at the date of this Prospectus is:

Name	Average Cost of Acquisition per Equity Share (in ₹)
Dr. Tushar Suvagiya	1.67
Dr. Subhash Padmani	1.67
Dr. Ravi Apte	1.67

The weighted average price at which the equity shares were acquired by our Promoters in the one year preceding the date of this Prospectus.

Name	No. of Equity Shares Acquired during last one Year	Weighted Average Price ¹⁾ (in ₹ per equity share)
Dr. Tushar Suvagiya	43,50,000	Nil
Dr. Subhash Padmani	1,87,500	Nil
Dr. Ravi Apte	1,50,000	Nil

¹⁾Weighted Average Price of Promoter is Nil due to Bonus Issue of Equity Shares dated July 31, 2022 and November 07, 2022.

The Issue Price is ₹60.00/- per Equity Share.
 The Issue Price (is determined by our Company in consultation with the Lead Manager) as stated in the chapter titled on "Basis for Issue Price" beginning on page 109 of the Prospectus should not be taken to be indicative of the market price of the equity shares after the equity shares are listed. No assurance can be given regarding an active and/or sustained trading in the equity shares of our company nor regarding the price at which the equity shares will be traded after listing.

GENERAL RISK: Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Issue unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors must rely on their own examination of our Company and the Issue, including the risks involved. The Equity Shares in the Issue have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the contents of this Prospectus. Specific attention of the investors is invited to "Risk Factors" on page no. 30 of this Prospectus.

CREDIT RATING: This being the issue of Equity Shares, credit rating is not required.

DEBENTURE TRUSTEES: As this is an issue of Equity Shares, the appointment of Trustees is not required.

IPO GRADING: Since this issue is made in terms of Chapter IX of the SEBI (ICDR) Regulations, there is no requirement of appointing an IPO Grading Agency.

BASIS OF ISSUE PRICE: The Issue Price has been determined by our Company in consultation with the Lead Manager on the basis of the key business strengths. The face value of the Equity Shares is ₹5/- and Issue Price is ₹60/- per Equity Shares and is 12 times of the face value. Investors should read the following basis with the sections titled "Risk Factors" and "Financial Information" and the chapter titled "Our Business" beginning on page no. 30, 209 and 126 respectively, of this Prospectus to get a more informed view before making any investment decisions. The trading price of the Equity Shares of our Company could decline due to these risk factors and you may lose all or part of your investments.

INFORMATION AS REQUIRED UNDER SECTION 30 OF THE COMPANIES ACT, 2013: Contents of Main Objects as per Memorandum of Association of our Company.

MAIN OBJECTS AS PER MEMORANDUM OF ASSOCIATION OF THE COMPANY
 For information on the Main Objects of the Company, please see "History and Certain Corporate Matters" on page no. 166 of the Prospectus and Clause III of the Memorandum of Association of our Company. The Memorandum of Association of the Company is a material document which is available for inspection in relation to the Issue. For further details, please see "Material Contracts and Documents for Inspection" on page no. 426 of the Prospectus.

LIABILITY OF MEMBERS: Liability of the Members of the Company is Limited.

AMOUNT OF SHARE CAPITAL OF OUR COMPANY AND CAPITAL STRUCTURE: Authorised Share Capital is ₹12,00,00,000 divided into 2,40,00,000 Equity Shares of face value of ₹5.00/- each. Issued, Subscribed and Paid-up Share Capital prior to the issue is ₹8,10,00,000 divided into 1,62,00,000 Fully Paid Equity Shares of ₹ 5.00/- each. Proposed Post Issue Paid-up Share Capital ₹11,30,00,000 divided into 2,26,00,000 Equity Shares of ₹ 5.00/- each. For details of the Share Capital and Capital Structure of the Company, please refer to chapter titled "Capital Structure" on page no. 73 of the Prospectus.

NAME OF THE SIGNATORIES TO MEMORANDUM OF ASSOCIATION AND THE NUMBER OF SHARES SUBSCRIBED BY THEM

Dr. Tushar Suvagiya and Dr. Subhash Padmani were the original subscribers to the Memorandum of Association who subscribed 5,000 and 5,000 Equity Shares each respectively of ₹10.00/- each aggregating to 10,000 Equity Shares.

LEAD MANAGER TO THE ISSUE	REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER
 NIRBHAY CAPITAL SERVICES PRIVATE LIMITED 201, Maruti Crystal, Opp. Rajpath Club, S.G Highway, Bodakdev, Ahmedabad 380054, Gujarat, India Tel No.: +91 79 48970649; +91 9727734956 Investor Grievance Email: ipo@nirbhaycapital.com Website: www.nirbhaycapital.com; Contact Person: Akshesh Dave SEBI Registration No.: INM000011393	 LINK INTIME INDIA PRIVATE LIMITED C-101, 247 Park, 1st Floor, L.B.S. Marg, Vikhroli West, Mumbai - 400083, Maharashtra, India. Tel No.: +91 22 49186200 Fax No: N.A Investor Grievance E-Mail: aatmajhealthcare.smeipo@linkintime.co.in Email: aatmajhealthcare.smeipo@linkintime.co.in Website: www.linkintime.co.in Contact Person: Shanti Gopalkrishnan SEBI Registration No.: INR000004058	 AATMAJ HEALTHCARE LIMITED Mrs. Radhika Hissaria "Jupiter Hospital", Opp. ICAI Bhavan, Sunpharma Ataladra Road, Vadodara-390012, Gujarat, India. Telephone No.: + 919714059465 Website: www.jupiterhospitalvadodara.com; E-Mail: cs@jupiterhospitalvadodara.com Investors can contact the Compliance officer or the Registrar in case of any Pre-Issue or Post-Issue related problems such as non-receipt of letters of allotment, credit of allotted Equity Shares in the respective beneficiary account etc.

AVAILABILITY OF PROSPECTUS: Investors should note that Investment in Equity Shares involves a high degree of risk and investors are advised to refer to the Prospectus and the Risk Factors contained therein, before applying in the Issue. Full copy of the Prospectus will be available at the website of SEBI at www.sebi.gov.in, the website of Stock Exchange at www.nseindia.com, the website of our Company at www.jupiterhospitalvadodara.com and also on website of Lead Manager at www.nirbhaycapital.com.

AVAILABILITY OF APPLICATION FORMS: Application Forms can be obtained from the Registered Office of Aatmaj Healthcare Limited and the Lead Manager to the Issue – Nirbhay Capital Services Private Limited. Application forms shall be available at selective location of Registered Brokers, Bankers to the Issue, RTA and Depository Participants. Application Forms can be obtained from the website of National Stock Exchange of India Limited and at the Designated Branches of SCSBs, the list of which is available on the website of NSE and SEBI.

APPLICATIONS SUPPORTED BY BLOCKED AMOUNT ("ASBA"): The investors are required to fill the application form and submit the same to the relevant SCSBs at the specific locations or registered brokers at the broker centers or RTA or DPs. The SCSBs will block the amount in the account as per the authority contained in application form. On allotment, amount will be unblocked and account will be debited only to the extent required to be paid for allotment of shares. Hence, there will be no need of refund. For more details on the ASBA process, please refer to the details given in Application Form and the Prospectus and also please refer to the chapter titled "Issue Procedure" on page no. 321 of the Prospectus.

APPLICATION SUPPORTED WITH UNIFIED PAYMENTS INTERFACE ("UPI"): APPLICATION SUPPORTED WITH UNIFIED PAYMENTS INTERFACE: Investors are advised to carefully refer SEBI Circular SEBI/HO/CFD/DIL2/CIR/P/2018/138 dated November 01, 2018 and as modified through its SEBI circular (SEBI/HO/CFD/ DIL2/CIR/P/2019/S0) dated April 3, 2019, SEBI circular (SEBI/HO/CFD/DIL2/CIR/P/2019/76) dated June 28, 2019, SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2019/8S dated July 26, 2019, SEBI Circular SEBI/HO/CFD/DCR2/CIR/P/2019/133 dated November 08, 2019, SEBI Circular No. SEBI/HO/CFD/DIL2/CIR/P/2020/50 dated March 30, 2020, SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2021/2480/1/M dated March 16, 2021, SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2021/47 dated March 31, 2021, SEBI Circular no. SEBI/HO/CFD/DIL2/P/CIR/2021/570 dated June 2, 2021, SEBI Circular no. SEBI/HO/CFD/DIL2/CIR/P/2022/45 dated April 5, 2022 and SEBI Circular no. SEBI/HO/CFD/DIL2/CIR/P/2022/51 dated April 20, 2022 and any subsequent circulars or notifications issued by SEBI in this regard for the procedure to be followed for applying through UPI. Retail Individual Investor have to apply through UPI Mechanism. Retail Individual Investor whose bank is not live on UPI as on date of this circular, may use the other alternate channels available to them viz. Submission of application form with SCSBs/ using the facility linked online trading, demat and bank account list. For further details, please refer the chapter titled "Issue Procedure" beginning on page no. 321 of the Prospectus.

Discount: Not Applicable

Sponsor Banker/ Banker to the Issue and Refund Banker to the Issue: Axis Bank Limited

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Prospectus.

Investor should read the Prospectus carefully, including the "Risk Factors" beginning on page no. 30 of the Prospectus before making any investment decision.

**For AATMAJ HEALTHCARE LIMITED
 On behalf of the Board of Directors
 Sd/-
 Dr. Tushar Suvagiya
 Managing Director
 DIN: 06802410**

Date: June 14, 2023
Place: Vadodara, Gujarat

Disclaimer: AATMAJ HEALTHCARE LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, an Initial Public Issue of its Equity Shares and has filed the Prospectus with the Registrar of Companies, Ahmedabad. The Prospectus is available on the website of SEBI at www.sebi.gov.in, the website of the Lead Manager at www.nirbhaycapital.com, website of the National Stock Exchange of India Limited at www.nseindia.com and website of the Issuer Company at www.jupiterhospitalvadodara.com. For details, investors should refer to and rely on the Prospectus including the section titled "Risk Factors" beginning on page no. 30 of the Prospectus.

The Equity Shares in this Issue have not been and will not be registered under the US Securities Act 1933, as amended (the "Securities Act") or any state securities laws in the United States and may not be issued or sold within the United States or to, or for the account or benefit of, "U.S. persons" (as defined in Regulation S of the Securities Act), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Accordingly, the Equity Shares will be issued and sold (i) within the United States only to persons reasonably believed to be "Qualified Institutional Buyers" (as defined in Rule 144A of the Securities Act) under Section 4(a) of the Securities Act, and (ii) outside the United States in offshore transaction in reliance on Regulation "S" under the Securities Act and the applicable laws of the jurisdiction where those Issue and sales occur.
 The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be issued or sold, and Application may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction.